TETRALOGIC PHARMACEUTICALS CORP Common Stock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch TLOG and buy or sell other stocks, ETFs, and their options commission-free!

About TLOG

TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel small molecule therapeutics in oncology and infectious diseases. Its products include Birinapant and SHAPE. 

CEO
J. Kevin Buchi, MBA, CPA
CEOJ. Kevin Buchi, MBA, CPA
Employees
11
Employees11
Headquarters
Malvern, Pennsylvania
HeadquartersMalvern, Pennsylvania
Founded
2001
Founded2001
Employees
11
Employees11

TLOG Key Statistics

Market cap
2.45K
Market cap2.45K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.64K
Average volume1.64K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.0002
52 Week high$0.0002
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

With a market cap of 2.45K, TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) trades at $0.00.

TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) stock opened on 2026-09-08 at —. The price climbed to — and dipped to —.

TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) shares are trading with a volume of 0, against a daily average of 1.64K.

In the last year, TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.

In the last year, TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.